[go: up one dir, main page]

WO2025210259A1 - Compositions pour produire une expérience de type cigarette fabriquée en usine - Google Patents

Compositions pour produire une expérience de type cigarette fabriquée en usine

Info

Publication number
WO2025210259A1
WO2025210259A1 PCT/EP2025/059344 EP2025059344W WO2025210259A1 WO 2025210259 A1 WO2025210259 A1 WO 2025210259A1 EP 2025059344 W EP2025059344 W EP 2025059344W WO 2025210259 A1 WO2025210259 A1 WO 2025210259A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
composition
ethyl
methyl
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/059344
Other languages
English (en)
Inventor
Priscila Brasil de Souza Cruz
Samuel KAISER
Douglas William MENEZES FLORES
Camila Assis
Maurilio Gustavo NESPECA
Liliane Medianeira Favero Porte
Grace Jenske
Giovana DA SILVA PINHEIRO
Julia Lilian Gauderth de Azevedo
Liane Valadao VIEIRA BOKOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicoventures Trading Ltd
Original Assignee
Nicoventures Trading Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicoventures Trading Ltd filed Critical Nicoventures Trading Ltd
Publication of WO2025210259A1 publication Critical patent/WO2025210259A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine

Definitions

  • Smoking articles such as cigarettes, cigars and the like burn tobacco during use to create tobacco smoke.
  • Alternatives to these types of articles release an inhalable aerosol or vapour by releasing compounds from a substrate material by heating without burning.
  • These may be referred to as non-combustible smoking articles, aerosol generating assemblies or non- combustible aerosol provision systems.
  • a heating device which releases compounds by heating, but not burning, a solid aerosolisable material.
  • This solid aerosolisable material may, in some cases, contain a tobacco material.
  • the heating volatilises at least one component of the material, typically forming an inhalable aerosol.
  • These products may be referred to as heat- not-burn devices, tobacco heating devices or tobacco heating products (THP).
  • THP tobacco heating products
  • e-cigarette / tobacco heating product hybrid devices also known as electronic tobacco hybrid devices.
  • These hybrid devices contain a liquid source (which may or may not contain nicotine) which is vaporised by heating to produce an inhalable vapour or aerosol.
  • the device additionally contains a solid aerosolisable material (which may or may not contain a tobacco material) and components of this material are entrained in the inhalable vapour or aerosol to produce the inhaled medium.
  • vapour products which are handheld, battery-powered devices that heat a liquid (called an e-liquid) to produce an inhalable aerosol, commonly known as vapour.
  • e-liquid a liquid
  • vapour an inhalable aerosol
  • the compositions used in tobacco heated products and vaping platforms can also be used in oral products which are ingested by the consumer.
  • a composition comprising at least three of the following compounds (hereinafter “List 1”): nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1,2,3,4,5,6-Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; and ferulic acid.
  • the composition comprises at least 4 of the compounds from List 1. In embodiments, the composition comprises at least 5 of the compounds from List 1. In embodiments, the composition comprises at least 6 of the compounds from List 1. embodiments, the composition comprises at least 7 of the compounds from List 1. In embodiments, the composition comprises at least 8 of the compounds from List 1. In embodiments, the composition comprises at least 9 of the compounds from List 1. In embodiments, the composition comprises at least 10 of the compounds from List 1. In embodiments, the composition comprises at least 11 of the compounds from List 1. In embodiments, the composition comprises at least 12 of the compounds from List 1. In embodiments, the composition comprises at least 13 of the compounds from List 1. In embodiments, the composition comprises at least 14 of the compounds from List 1. n embodiments, the composition comprises at least 15 of the compounds from List 1.
  • the composition comprises at least 16 of the compounds from List 1. In embodiments, the composition comprises at least 17 of the compounds from List 1. In embodiments, the composition comprises at least 18 of the compounds from List 1. In embodiments, the composition comprises at least 19 of the compounds from List 1. In embodiments, the composition comprises all of the compounds from List 1.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; and megastigmatrienone.
  • the composition further comprises one or more of the following compounds (hereinafter “List 2”): nicotine; 2-hydroxy-4-methyl-2-cyclopenten-1-one; quinic acid; sucrose; N-(1-deoxy-1-fructosyl)proline; 3,4-dimethyl-2(3H)-furanone; lipid peroxidation inhibitor 1; pseudooxynicotine and/or oxynicotine; 2-ethyl-quinoxaline; 1 ,2, 3,4,5, 6-hexahydro-7H- cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; rutin; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; 3,5-di(1 ,1-dimethylethyl)-4-hydroxy- benzaldehyde; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid
  • the composition further comprises one or more of the following compounds (hereinafter “List 3”): 2-methoxy-phenol; p-cresol; furaneol; indole; 3-methyl-pentanoic acid; butanoic acid; 3-methyl-butanoic acid; D-limonene; acetophenone; 1-(4-methylphenyl)- ethanone; vanillin; 2,6-dimethoxy-phenol; benzaldehyde; benzeneacetic acid; 2-methyl- butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; and octanoic acid.
  • List 3 2-methoxy-phenol
  • p-cresol furaneol
  • indole 3-methyl-pentanoic acid
  • butanoic acid 3-methyl-butanoic acid
  • D-limonene acetophenone
  • the composition further comprises one or more of the following compounds (hereinafter “List 4”): 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 5-methyl-2- furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; benzaldehyde; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; 2-methoxy-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1- (1H-pyrrol-2-yl)-ethanone; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; octanoic acid; 2,6-dimethoxy-phenol; 2-methyl-propanoic acid; 3-methyl-butanoic acid; D-limonene; 2- acetyl-5-methylfuran
  • the composition comprises at least 3 compounds from List 1, at least 3 compounds from List 2, at least 3 compounds from List 3 and at least 3 compounds from List 4. In embodiments, the composition comprises at least 5 compounds from List 1, at least 5 compounds from List 2, at least 5 compounds from List 3 and at least 5 compounds from List 4. In embodiments, the composition comprises at least 10 compounds from List 1, at least 10 compounds from List 2, at least 10 compounds from List 3 and at least 10 compounds from List 4.
  • At least 1 of the compounds included in the composition from List 1 is a purified compound. In embodiments, at least 3 of the compounds included in the composition from List 1 are purified compounds. In embodiments, at least about 25%, at least about 50% or at least about 75% of the compounds included in the composition from List 1 are purified compounds. In embodiments, all of the compounds included in the composition from List 1 are purified compounds.
  • the composition from List 2 is a purified compound. In embodiments, if present at least 3 of the compounds included in the composition from List 2 are purified compounds. In embodiments, if present at least about 25%, at least about 50% or at least about 75% of the compounds included in the composition from List 2 are purified compounds. In embodiments, if present all of the compounds included in the composition from List 2 are purified compounds.
  • composition from List 3 is a purified compound. In embodiments, if present at least 3 of the compounds included in the composition from List 3 are purified compounds. In embodiments, if present at least about 25%, at least about 50% or at least about 75% of the compounds included in the composition from List 3 are purified compounds. In embodiments, if present all of the compounds included in the composition from List 3 are purified compounds.
  • the composition is not, or does not contain, a tobacco extract.
  • the composition is formed from a tobacco extract.
  • composition or tobacco extract comprises some, but not all, of the compounds listed in List 1.
  • the composition comprises a tobacco extract.
  • one or more of the key chemical markers described herein may be present in or provided from the extract.
  • the composition comprises a tobacco extract and at least one further compound, wherein said at least one further compound is one of the key chemical markers described herein.
  • the at least one further compound is not otherwise present in the tobacco extract (i.e. it must be added to the extract).
  • the composition comprises a tobacco extract and at least 10 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 11 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 12 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 13 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 14 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 15 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 16 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 17 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 18 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and at least 19 further compounds from List 1. In embodiments, the composition comprises a tobacco extract and, in addition, all of the compounds from List 1 .
  • the composition comprises a tobacco extract and at least 1 (such as at least
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 1 and 3.
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 1 and 4.
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5)
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 2 and 4. In embodiments, the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 3 and 4.
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 1 , 2, 3 and 4.
  • the composition is a tobacco extract.
  • the composition comprises a total of from about 0.00001 to about 5 wt% of the compounds listed in Lists 1 , 2 and 3. In embodiments, the composition comprises a total of from about 0.0001 to about 2 wt% of the compounds listed in Lists 1 , 2 and 3. In embodiments, the composition comprises a total of from about 0.001 to about 1 wt% of the compounds listed in Lists 1, 2 and 3. In embodiments, the composition comprises a total of from about 0.005 to about 0.5 wt% of the compounds listed in Lists 1 , 2 and 3. In embodiments, the composition comprises a total of from about 0.00001 to about 5 wt% of the compounds listed in Lists 1, 2, 3 and 4.
  • the composition is an aerosol-generating composition.
  • the aerosolgenerating composition may be a solid, semi-solid (e.g. gel) or liquid. In embodiments the composition is a solid. In embodiments the aerosol-generating composition is a gel. In embodiments the aerosol-generating composition is a liquid.
  • the composition is a composition for oral delivery of the compounds contained therein.
  • the composition (e.g. the aerosol-generating composition) further comprises an aerosol-former material, such as glycerol and/or propylene glycol.
  • an aerosol-former material such as glycerol and/or propylene glycol.
  • the total TSNA content of the compositions or materials described herein is less than about 800 ppb, less than about 500 ppb, less than about 200 ppb, less than about 100 ppb, less than about 50 ppb, less than about 20 ppb, or less than about 10 ppb. In embodiments there are no TSNAs in the compositions or materials described herein.
  • a non-combustible aerosol provision system comprising a composition or consumable as described herein and a non-combustible aerosol provision device, the non-combustible aerosol provision device comprising an aerosol-generation device arranged to generate aerosol from the composition or consumable when the composition or consumable is used with the non-combustible aerosol provision device.
  • the aerosol-generation device may be a tobacco heating device, also known as a heat-not- burn device.
  • the aerosol-generation device may be a vaping device or e-cigarette.
  • an aerosol-free delivery system comprising a composition or consumable as described herein.
  • Said aerosol- free delivery system may be configured to deliver the composition or consumable to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as oral tobacco which includes snus or moist snuff.
  • an aerosol formed from a non-combustible aerosol provision device wherein the aerosol comprises the composition described herein, e.g. at least three of the following compounds: nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1- fructosyl)proline; sucrose; Type I sucrose ester - GV - I0; Type I sucrose ester - GIV - I0; chlorogenic acid; 1,2,3,4,5,6-Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H- pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - I0; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type
  • a method of forming a composition as described herein comprising mixing the compounds together.
  • the compounds may first be isolated or purified.
  • a method of forming a composition as described herein comprising forming a tobacco extract, and optionally adding one or more of the key chemical markers (e.g. key taste markers) described herein.
  • the one or more chemical markers added may first be isolated or purified.
  • one or more of the key chemical markers or additional key chemical markers are applied to the slurry during and/or after steps (b) and/or (c).
  • chemical markers which may first be isolated or purified
  • Figure 1 is a schematic (exploded) diagram of an electronic aerosol provision system such as an e-cigarette.
  • Figure 2 is a block diagram of an aerosol generating device, such as a tobacco heated product.
  • the inventors have identified a range of compounds (also called chemical markers) responsible for these flavour dimensions. For example, some compounds or chemical markers have been found to contribute towards providing the sense of a cigarette, whilst some contribute towards providing the taste of a cigarette and some contribute towards providing the flavour of a cigarette.
  • the compounds were identified by collecting and analysing the smoke produced from burning and smoking cigarettes, as well as using machine learning and human sensory assessment.
  • the “sense” of a cigarette it is meant the overall feel of smoking a cigarette, which includes, for example, impact, irritation, harshness, mouth drying, and mouth coating.
  • the “taste” of a cigarette includes known taste attributes, such as hay-like, bread-like, nutty, bitter, smoky, tannin, resinous, musk, etc.
  • the “flavour” of a cigarette includes known flavour attributes, such as creamy, fruity, floral, green, spicy, savoury, roasted, woody, etc. During their investigations, the inventors also identified all of the compounds which are present in the smoke produced by burning different cigarettes containing types of tobacco.
  • the inventors also formed tobacco extracts from the same tobacco, and identified all of the compounds which were present in these extracts. They found some compounds were present in the tobacco smoke, but not in the tobacco extracts. These compounds are also considered to be chemical markers responsible for the cigarette-like experience. They are termed the chemical smoke markers (i.e. chemical markers for smoke) herein. Over 100 chemical smoke markers were found for each extract tested (i.e. there were over 100 chemicals present in tobacco smoke but not in a tobacco extract formed from the same tobacco). These chemical markers will contribute towards recreating the feel, taste and/or flavour of smoke produced when burning a cigarette. Such compounds may not be produced when forming a tobacco extract, or when heating (but not burning) the tobacco extract or a composition comprising said extract.
  • the inventors have found that the following compounds (referred to herein as the “key taste markers” or “List 1”) are important for creating the taste of a cigarette: nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1- fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1,2,3,4,5,6-Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H- pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; and
  • the inventors have found that the following compounds (referred to herein as the “key sense markers” or “List 2”) are important for creating the sense of a cigarette: nicotine; 2-hydroxy-4- methyl-2-cyclopenten-1-one; quinic acid; sucrose; N-(1-deoxy-1-fructosyl)proline; 3,4- dimethyl-2(3H)-furanone; lipid peroxidation inhibitor 1; pseudooxynicotine and/or oxynicotine; 2-ethyl-quinoxaline; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; rutin; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; 3,5-di(1 ,1-dimethylethyl)-4-hydroxy-benzaldehyde; L-alpha-amino-1
  • the key sense markers will contribute towards simulating the sense of a cigarette.
  • the key taste markers will contribute towards simulating the taste of a cigarette.
  • the key flavour markers will contribute towards simulating the flavour of a cigarette.
  • a tobacco extract which does not contain all of the key chemical markers identified herein can be supplemented with additional key chemical markers. That is, one or more of the key chemical markers can be added to a tobacco extract. Said tobacco extract may, in some embodiments, already contain one or more of the key chemical markers identified herein.
  • compositions which may be absent from a tobacco extract, but present in smoke formed by burning the same tobacco used to form the extract (i.e. the “smoke markers”). This further improves the cigarette-like experience produced by the composition.
  • the invention provides a composition (e.g. a solid, semi-solid or liquid composition) comprising at least three of the key chemical taste markers, namely the following compounds: nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1,2, 3,4,5, 6-Hexahydro-7H-cyclopenta[b]pyridin-7- one; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; retinol; quinic acid; Type I sucrose ester- Gill - IO; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO;
  • the inventors have found that by combining at least 3 (e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15) of the key taste markers (i.e. the compounds from List 1), a composition can be created which will achieve a more cigarette-like taste than a composition without any of these markers (e.g. when used in a non-combustible aerosol provision system).
  • the key taste markers i.e. the compounds from List 1
  • sucrose esters groups are related to the sets of organic acid(s) that esterify the hydroxyl groups in the glucose unit.
  • Five major sucrose esters groups include G1 to G5, for each sucrose ester type (as set out below).
  • Sucrose esters are named by type (e.g. T1, Tl or Type 1 means Sucrose Ester Type I), group (e.g. GV or G5 means CsCeCs acids esterify the hydroxy groups on the glucose unit) and the number of double bonds on the acid groups (e.g. IO means zero double bonds, or saturated acid groups).
  • type e.g. T1, Tl or Type 1 means Sucrose Ester Type I
  • group e.g. GV or G5 means CsCeCs acids esterify the hydroxy groups on the glucose unit
  • the number of double bonds on the acid groups e.g. IO means zero double bonds, or saturated acid groups.
  • the composition comprises all of the key taste markers.
  • the composition comprises at least nicotine.
  • the composition comprises at least nicotine; and pseudooxynicotine and/or oxynicotine.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; and lipid peroxidation inhibitor 1.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; and scopoletin.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; and N-(1-deoxy-1-fructosyl)proline.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; and sucrose.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; and Type I sucrose ester - GV - IO.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; and Type I sucrose ester - GIV - IO.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; and chlorogenic acid.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; and 1,2,3,4,5,6-Hexahydro-7H-cyclopenta[b]pyridin-7-one.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; and L-alpha-amino-1H-pyrrole-1-hexanoic acid.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; and quinic acid.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; and Type I sucrose ester - Gill - IO.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; and rutin.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 ,2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; and megastigmatrienone.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; and 2-ethyl-5- methyl-pyridine.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; 2-ethyl-5- methyl-pyridine; and 16-hydroxy-hexadecanoicacid.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; and Type III sucrose ester - GV - IO.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; chlorogenic acid; 1 , 2, 3, 4,5,6- Hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; retinol; quinic acid; Type I sucrose ester - Gill - IO; rutin; megastigmatrienone; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; and ferulic acid.
  • the composition also comprises 1 or more of the key sense markers (see List 2). In embodiments, the composition also comprises 2 or more of the key sense markers (see List 2). In embodiments, the composition also comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of the key sense markers (see List 2).
  • the composition also comprises 1 or more of the key flavour markers (see List 3). In embodiments, the composition also comprises 2 or more of the key flavour markers (see List 3). In embodiments, the composition also comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of the key flavour markers (see List 3).
  • the composition also comprises 1 or more of the key smoke markers (see List 4). In embodiments, the composition also comprises 2 or more of the key smoke markers (see List 4). In embodiments, the composition also comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of the key smoke markers (see List 4).
  • the composition comprises, in addition to the key taste markers, at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of each of the key sense markers and key smoke markers (see Lists 2 and 4 respectively).
  • the composition comprises, in addition to the key taste markers, at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of each of the key flavour markers and key smoke markers (see Lists 3 and 4 respectively).
  • the composition comprises, in addition to the key taste markers, at least 1 , at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 of each of the key sense markers, key flavour markers and key smoke markers (see Lists 2, 3 and 4 respectively).
  • the composition comprises at least 3 (e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15) compounds from List 1, at least 3 (e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15) compounds from List 2, at least 3 (e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15) compounds from List 3 and at least 3 (e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15) compounds from List 4.
  • at least 3 e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15
  • at least 3 e.g. at least 4, at least 5, at least 6, at least 8, at least 10 or at least 15
  • the compounds may be the same or different.
  • a single compound e.g. nicotine
  • the compounds must be different.
  • a single compound e.g. nicotine
  • any compound(s) included in the composition from List 2 and/or List 4 must be different to those already present in the composition from List 1.
  • pseudooxynicotine and/or oxynicotine means that one or both of these compounds may be present. In some embodiments, only one of these is present (i.e. “pseudooxynicotine or oxynicotine”).
  • composition comprises all of the compounds listed in Lists 1, 2 and 3.
  • the composition comprises all of the compounds listed in Lists 1 , 2, 3 and 4. In embodiments, the composition comprises a total of up to about 10 wt%, 5 wt%, 4 wt%, 3, wt%, 2 wt%, 1 wt% or 0.5 wt%, such as from about 0.0001 to about 2 wt%, from about 0.001 to about 1 wt% or from about 0.005 to about 0.5 wt% of the compounds as defined in List 1.
  • the composition comprises a total of up to about 10 wt%, 5 wt%, 4 wt%, 3, wt%, 2 wt%, 1 wt% or 0.5 wt%, such as from about 0.0001 to about 2 wt%, from about 0.001 to about 1 wt% or from about 0.005 to about 0.5 wt% of the compounds as defined in List 2.
  • the composition comprises a total of up to about 10 wt%, 5 wt%, 4 wt%, 3, wt%, 2 wt%, 1 wt% or 0.5 wt%, such as from about 0.0001 to about 2 wt%, from about 0.001 to about 1 wt% or from about 0.005 to about 0.5 wt% of the compounds listed in Lists 1 , 2 and 3.
  • the composition comprises a total of up to about 10 wt%, 5 wt%, 4 wt%, 3, wt%, 2 wt%, 1 wt% or 0.5 wt%, such as from about 0.0001 to about 2 wt%, from about 0.001 to about 1 wt% or from about 0.005 to about 0.5 wt% of the compounds listed in Lists 1, 2, 3 and 4.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; and megastigmatrienone.
  • the composition may comprise or be a tobacco extract.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; megastigmatrienone; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl- phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy- phenol; and 2,6-dimethoxy-phenol.
  • the composition may comprise or be a tobacco extract.
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 2-methyl-3-butyl-pyrazine; megastigmatrienone; 2- methyl-butanoic acid; and acetic acid.
  • the composition may comprise or be a tobacco extract.
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 2-methyl-3-butyl-pyrazine; megastigmatrienone; 3- ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2- hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl- phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6- dimethoxy-phenol.
  • the composition may comprise or be a tobacco extract.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; megastigmatrienone; 2-methyl-butanoic acid; acetic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1- one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1- one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4- vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6-dimethoxy-phenol.
  • the composition may comprise or be a tobacco extract.
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 2-methyl-3-butyl-pyrazine; megastigmatrienone; 2- methyl-butanoic acid; acetic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2- ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2- methoxy-phenol; and 2,6-dimethoxy-phenol.
  • the composition comprises at least nicotine; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; 2-methyl-3-butyl-pyrazine; megastigmatrienone; solanesol; and 16-hydroxy-hexadecanoicacid.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE).
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; megastigmatrienone; 3-methyl-pentanoic acid; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; and acetic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE).
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; megastigmatrienone; 3-ethyl-2- hydroxy-2 - cyclopenten-1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; benzaldehyde; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; 2-methoxy-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2- methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; octanoic acid; and 2,
  • the composition comprises at least nicotine; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 16-hydroxy-hexadecanoicacid; 2-ethyl-5-methyl-pyridine; 2- methyl-3-butyl-pyrazine; megastigmatrienone; solanesol; 3-methyl-pentanoic acid; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; and acetic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE).
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; 16-hydroxy-hexadecanoicacid; megastigmatrienone; 3-methyl-pentanoic acid; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid;
  • composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE).
  • SFE supercritical fluid extraction
  • the composition comprises at least nicotine; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 16-hydroxy-hexadecanoicacid; 2-ethyl-5-methyl-pyridine; 2- methyl-3-butyl-pyrazine; megastigmatrienone; solanesol; 3-methyl-pentanoic acid; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 3- ethyl-2-hydroxy-2-cyclopenten-1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3- methyl-pyridine; butanoic acid; 3-ethyl-pyridine; benzaldehyde; 2-hydroxy-3-methyl-2
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE).
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; retinol; megastigmatrienone; Type III sucrose ester - GV - 10; and L-alpha-amino-1H-pyrrole-
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; and Type III sucrose ester - GV - IO.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE).
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type III sucrose ester - GV - IO; 2-methoxy-phenol; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; benzaldehyde;
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE).
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type III sucrose ester - GV
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type III sucrose ester - GV
  • composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE).
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - 10; retinol; Type III sucrose ester - GV - 10; 3-methyl-pentanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; and 2-methyl-propanoic acid.
  • the composition may comprise or be a tobacco extract, which may be an extract of a blend of flue- cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - IO; retinol; Type III sucrose ester - GV - IO; megastigmatrienone; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2- ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1-(1 H-pyrrol-2-yl)-ethanone; 2- methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6-dimethoxy-phenol.
  • the composition may comprise or be a tobacco extract, which may be an extract of a blend of flue-cured Virginia, air-cured burley
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; Type I sucrose ester- GV - IO; Type III sucrose ester- GV - IO; 3-methyl- pentanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; and 2-methyl-propanoic acid.
  • the composition may comprise or be a tobacco extract, which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; Type I sucrose ester - GV - IO; Type III sucrose ester - GV - IO; 3-ethyl- 2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl- pyrazine; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1-(1 H-pyrrol-2-yl)-ethanone; 2-methoxy-4- vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6-dimethoxy-phenol.
  • the composition may comprise or
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - IO; retinol; Type III sucrose ester - GV - IO; 3-methyl-pentanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1- one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2- hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl- phenol; 3-ethyl-phenol; 1-(1 H-pyrrol-2-yl)-ethanone; 2-methoxy-4
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 2-methyl-3-butyl-pyrazine; megastigmatrienone; and L-alpha-amino-1 H-pyrrole-1 -hexanoic acid.
  • the composition may comprise or be a tobacco extract, which may be an extract of flue-cured Virginia tobacco.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; 2-methyl-butanoic acid; and acetic acid.
  • the composition may comprise or be a tobacco extract, which may be an extract of flue-cured Virginia tobacco.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1 -hexanoic acid; 3-ethyl-2-hydroxy-2- cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2- cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2- methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; 2,6-dimethoxy-phenol; 2-methyl-propanoic acid; and vanillin.
  • the composition may comprise or be a tobacco extract, which may be an extract of flue-cured Virginia tobacco.
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; 2-methyl-butanoic acid; acetic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl- pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; 2,6- dimethoxy-phenol; 2-methyl-propanoic acid; and vanillin.
  • the composition may comprise or be a tobacco extract, which may be an extract of flue-cured Virginia tobacco.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; chlorogenic acid; 1 , 2, 3, 4,5,6- hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1H-pyrrole-1-hexanoic acid; quinic acid; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; and ferulic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SFE supercritical fluid extraction
  • the composition comprises at least nicotine; quinic acid; sucrose; N-(1- deoxy-1-fructosyl)proline; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; rutin; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; solanesol; chlorogenic acid; 16-hydroxy- hexadecanoicacid; and ferulic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SFE supercritical fluid extraction
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of flue-cured Virginia tobacco.
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; chlorogenic acid; 1 , 2, 3, 4,5,6- hexahydro-7H-cyclopenta[b]pyridin-7-one; L-alpha-amino-1H-pyrrole-1-hexanoic acid; quinic acid; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; ferulic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; butanoic acid; 3-ethyl
  • the composition comprises at least nicotine; quinic acid; sucrose; N-(1- deoxy-1-fructosyl)proline; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; rutin; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; solanesol chlorogenic acid; 16-hydroxy- hexadecanoicacid; ferulic acid; 3-methyl-pentanoic acid; benzeneacetic acid; 2-methyl- butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 3-ethyl-2-hydroxy-2-
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; retinol; megastigmatrienone; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - 10; Type I sucrose ester - Gill - 10; 16-hydroxy-hexadecanoicacid; and Type III sucrose ester - GV - IO.
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • SFE supercritical fluid extraction
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; retinol; megastigmatrienone; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; Type I sucrose ester - Gill - IO; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; benzaldehyde; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; aceto
  • the composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • the composition comprises at least nicotine; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; solanesol; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; Type I sucrose ester - GUI - IO; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV
  • composition may comprise or be a tobacco extract, which may be obtained using supercritical fluid extraction (SFE) and/or which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • SFE supercritical fluid extraction
  • the composition comprises at least nicotine; pseudooxynicotine and/or oxynicotine; 1 ,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; scopoletin; 2-ethyl-5- methyl-pyridine; retinol; megastigmatrienone; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; Type I sucrose ester - GUI - IO; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; 3-methyl-pentanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)- ethanone; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one
  • the composition comprises at least nicotine; 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; 1,2,3,4,5,6-hexahydro-7H-cyclopenta[b]pyridin-7-one; 2-ethyl-pyridine; scopoletin; 2-ethyl-5-methyl-pyridine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; solanesol; Type I sucrose ester - GV - IO; Type I sucrose ester - GIV - IO; Type I sucrose ester - Gill - IO; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - IO; 3-methyl-pentanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; benzeneacetic acid; 2-methyl-butanoic acid; pentanoic acid;
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; retinol; megastigmatrienone; Type III sucrose ester - GV - IO; and L-alpha-amino-1H-pyrrole- 1-hexanoic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; and Type III sucrose ester - GV - IO.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; retinol; megastigmatrienone; Type III sucrose ester - GV - IO; L-alpha-amino-1H-pyrrole-1- hexanoic acid; 2-methoxy-phenol; 3-methyl-butanoic acid; D-limonene; 1-(4-methylphenyl)- ethanone; benzaldehyde; 2-methyl-butanoic acid; acetic acid; and octanoic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; retinol; megastigmatrienone; Type III sucrose ester - GV - 10; L-alpha-amino-1H-pyrrole-1- hexanoic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3- ethyl-pyridine; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl- phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1-(1H-pyrrol-2-yl)-ethanone; 2-methoxy-4- vinylphenol; 4-ethyl-2-methoxy-phenol; 2,6-dimethoxy-phenol; 2-methyl-propanoic acid; vanillin; pentanoic acid; benzoic acid; triacetin; benzeneacetic acid
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type III sucrose ester - GV
  • composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of flue-cured Virginia tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; retinol; megastigmatrienone; Type III sucrose ester - GV - IO; L-alpha-amino-1H-pyrrole-1- hexanoic acid; 2-methoxy-phenol; 3-methyl-butanoic acid; D-limonene; 1-(4-methylphenyl)- ethanone; benzaldehyde; 2-methyl-butanoic acid; acetic acid; and octanoic acid; 3-ethyl-2- hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; tiglic acid; 2- hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl- phenol; 3-ethyl-phenol; 1-(1 H-pyrrol-2-yl)-e
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - IO; retinol; Type III sucrose ester - GV - IO; megastigmatrienone; and L-alpha-amino-1 H-pyrrole-1-hexanoic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - 10; retinol; Type III sucrose ester - GV - 10; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; 2-methoxy-phenol; 3-methyl-pentanoic acid; 3- methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; benzaldehyde; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; and octanoic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • SDE simultaneous distillation extraction
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - IO; retinol; Type III sucrose ester - GV - IO; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl- pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2-hydroxy-3-methyl-2- cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1- (1 H-pyrrol-2-yl)-ethanone; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; 2,6- dimethoxy-phenol; benzoic acid; triacetin; benzen
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type I sucrose ester - GV - IO; Type III sucrose ester - GV - IO; 2-methoxy-phenol; 3-methyl-pentanoic acid; 3-methyl- butanoic acid; 1-(4-methylphenyl)-ethanone; benzaldehyde; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; and octanoic acid.
  • the composition may comprise or be a tobacco extract, which may be obtained using simultaneous distillation extraction (SDE) and/or which may be an extract of a blend of fluor fluor flu
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type I sucrose ester - GV - IO; Type III sucrose ester - GV - IO; 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2-hydroxy-3-methyl-2- cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 1- (1H-pyrrol-2-yl)-ethanone; 2-methoxy-4-vinylphenol; 4-ethyl-2-me
  • the composition comprises at least pseudooxynicotine and/or oxynicotine; Type I sucrose ester - GV - IO; retinol; Type III sucrose ester - GV - IO; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; 2-methoxy-phenol; 3-methyl-pentanoic acid; 3- methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; benzaldehyde; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; octanoic acid; 3-ethyl-2- hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethylpyrazine; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone
  • the composition comprises at least 3,4-dimethyl-2(3H)-furanone; pseudooxynicotine and/or oxynicotine; retinol; 2-methyl-3-butyl-pyrazine; megastigmatrienone; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; Type I sucrose ester - GV - IO; Type III sucrose ester - GV - IO; 2-methoxy-phenol; 3-methyl-pentanoic acid; 3-methyl- butanoic acid; 1-(4-methylphenyl)-ethanone; benzaldehyde; 2-methyl-butanoic acid; pentanoic acid; hexanoic acid; acetic acid; 2-methyl-propanoic acid; octanoic acid; 3-ethyl-2- hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; trimethylpyr
  • compositions may further comprise 1 or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32 or 33) of the following compounds: 3-ethyl-2-hydroxy-
  • compositions may further comprise 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16 or 17) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2-hydroxy-
  • compositions may further comprise 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; benzaldehyde; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; 2-methoxy-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2- methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; octanoic acid; 2,6-dimethoxy-phenol; 2- methyl-propanoic acid; 3-methyl-butanoic acid; 1-(4-methylphenyl)-ethanone; vanillin; pentanoic acid; and benzeneacetic
  • compositions may further comprise 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2- hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl- phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6- dimethoxy-phenol.
  • 1 or more e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13
  • the compositions may further comprise 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; but
  • compositions may further comprise 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7 or 8) of the following compounds: 3-ethyl-2-hydroxy- 2-cyclopenten-1-one; 3-methyl-pyridine; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten- 1-one; 2-ethyl-phenol; 4-ethyl-phenol; 3-ethyl-phenol; and 2-methoxy-4-vinylphenol.
  • 1 or more e.g. 1 , 2, 3, 4, 5, 6, 7 or 8 of the following compounds: 3-ethyl-2-hydroxy- 2-cyclopenten-1-one; 3-methyl-pyridine; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten- 1-one; 2-ethyl-phenol; 4-ethyl-phenol; 3-ethyl-phenol; and 2-methoxy-4-vinylphenol.
  • the present invention provides for the formulation of a partially or totally synthetic or artificial composition.
  • at least one of the key taste markers may be a purified, isolated or synthetic compound.
  • a purified, isolated or synthetic compound may be obtained from a natural source (e.g. from tobacco), but before being added to the composition it will first have been purified or isolated.
  • the compound(s) may also be available commercially.
  • the claimed composition is not an extract of tobacco. In embodiments the composition does not comprise or contain a tobacco extract.
  • At least 1 e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20
  • at least 1 e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20
  • at least 1 e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20
  • at least 1 e.g. at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20
  • less than about 90%, less than about 80%, less than about 60%, less than about 50%, less than about 20% or less than about 10% of the key chemical markers included in the composition are purified compounds.
  • from about 10% to about 90% of the key chemical markers included in the composition is a purified, isolated or synthetic compound. In embodiments, from about 10% to about 50% of the key chemical markers included in the composition is a purified, isolated or synthetic compound. In embodiments, from about 10% to about 30% of the key chemical markers included in the composition is a purified, isolated or synthetic compound. In embodiments, from about 10% to about 20% of the key chemical markers included in the composition is a purified, isolated or synthetic compound.
  • numbered of markers obtained from percentages should be rounded up to the nearest whole number when a ranger refers to “at least” a certain percentage, and down to the nearest whole number when a ranger refers to “less than” a certain percentage. For example, at least 10% of 4 chemical markers would mean 1 or more, and less than 80% of 8 chemical markers would mean 6 or less.
  • At least 1 e.g. at Ieast 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18,
  • all of the key taste markers which are present are purified, isolated or synthetic compounds. In embodiments all of the key sense markers which are present are purified, isolated or synthetic compounds.
  • all of the key sense and taste markers which are present are purified, isolated or synthetic compounds.
  • all of the key sense and smoke markers which are present are purified, isolated or synthetic compounds.
  • all of the key taste and smoke markers which are present are purified, isolated or synthetic compounds.
  • flavour and smoke markers which are present are purified, isolated or synthetic compounds.
  • all of the key sense, taste and flavour markers which are present are purified, isolated or synthetic compounds.
  • all of the key sense, taste and smoke markers which are present are purified, isolated or synthetic compounds.
  • flavour and smoke markers which are present are purified, isolated or synthetic compounds. In embodiments all of the key taste, flavour and smoke markers which are present are purified, isolated or synthetic compounds.
  • the total number of compounds present in the composition can also be an indication of whether the composition is synthetic or naturally-derived. This is because tobacco extracts will often contain a large number of different chemical compounds. Any composition comprising a tobacco extract will often also contain a large number of different chemical compounds.
  • the total number of chemical compounds present in the compositions or materials described herein is less than about 500, such as less than about 300, less than about 200, less than about 150, less than about 100, less than about 80 or less than about 60.
  • total number of chemical compounds it is meant the number of different chemical compounds present at a detectable level.
  • the total number of chemical compounds means the number of different chemical compounds present at a level of 1 ppm or more.
  • a composition comprising (at least 1 ppm of) glycerol, propylene glycol, and all of the key taste markers described herein would contain 22 chemical compounds.
  • compositions comprising glycerol, propylene glycol and a commercially available tobacco extract might contain hundreds of different chemical compounds (e.g. more than 500, more than 300 or more than 200), each of which may be present in the amount of at least 1 ppm.
  • the total content of any one of NNN, NAT, NAB and NNK in the compositions or materials described herein is less than about 800 ppb, less than about 500 ppb, less than about 200 ppb, less than about 100 ppb, less than about 50 ppb, less than about 20 ppb, or less than about 10 ppb. In embodiments the total content of any one of NNN, NAT, NAB and NNK in the compositions or materials described herein is less than about 1 ppb. In embodiments the total TSNA content (i.e.
  • Other chemical compounds indicative of non-synthetic tobacco extracts might include formaldehyde and/or acetaldehyde.
  • the total content of formaldehyde and acetaldehyde in the compositions or materials described herein is less than about 100 ppm, less than about 50 ppm, less than about 10 ppm, less than about 5 ppm, less than about 2 ppm, or less than about 1 ppm.
  • a tobacco extract does not comprise any of the key chemical markers described herein, in which case these markers must be added to the extract to form a composition of the invention.
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from List 1. In embodiments, the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from List 2. In embodiments, the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from List 3. In embodiments, the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from List 4.
  • the composition comprises a tobacco extract and at least 1 (such as at least
  • the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 2 and 4. In embodiments, the composition comprises a tobacco extract and at least 1 (such as at least 2, 3, 4 or 5) further compound(s) from each of Lists 3 and 4.
  • said further compound(s) may be isolated or purified compounds.
  • the composition is a tobacco extract.
  • the tobacco may be cured or uncured, but in embodiments the tobacco is cured.
  • Cured tobacco may be flue-cured, air-cured and/or sun-cured.
  • any tobacco extract used in the present invention is an extract of cured Virginia tobacco.
  • any tobacco extract used in the present invention is an extract of flue-cured Virginia tobacco.
  • any tobacco extract used in the present invention is an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco.
  • any tobacco extract used in the present invention is obtained by simultaneous distillation extraction (SDE).
  • any tobacco extract used in the present invention is an extract of flue-cured Virginia tobacco and is obtained by supercritical fluid extraction (SFE).
  • any tobacco extract used in the present invention is an extract of a blend of flue-cured Virginia, air-cured burley and sun-cured oriental tobacco and is obtained by supercritical fluid extraction (SFE).
  • SFE supercritical fluid extraction
  • the liquid composition further comprises water.
  • the water may be present in any suitable amount. In one embodiment water is present in an amount of from about 1 wt%, 5 wt%, 10 wt%, 15 wt%, 20 wt% or 22 wt% to about 50 wt%, 40 wt%, 30 wt% or 27 wt%, based on the overall composition.
  • the liquid composition comprises from about 10 to about 50 wt% propylene glycol, such as from about 15 to about 40 wt%, or from about 20 to about 35 wt%
  • the liquid composition comprises from about 40 to about 60 wt% glycerol, from about 20 to about 35 wt% propylene glycol, and 0 to about 3 wt% nicotine.
  • the aerosol-generating composition or the aerosol-generating material may further comprise an aerosol-former material.
  • the aerosol-former material may comprise one or more constituents capable of forming an aerosol.
  • the aerosol-former material comprises one or more of glycerol, propylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, 1 ,3-butylene glycol, erythritol, meso-Erythritol, ethyl vanillate, ethyl laurate, a diethyl suberate, triethyl citrate, triacetin, a diacetin mixture, benzyl benzoate, benzyl phenyl acetate, tributyrin, lauryl acetate, lauric acid, myristic acid, and propylene carbonate.
  • glycerol propylene glycol
  • diethylene glycol triethylene glycol
  • tetraethylene glycol 1 ,3-butylene glycol
  • erythritol meso-Erythritol
  • ethyl vanillate ethyl laurate
  • the aerosol-generating composition or the aerosol-generating material comprises from about 1 wt%, 5 wt%, 10 wt%, 20 wt%, 30 wt% or 40 wt% to about 60 wt%, 55 wt%, 50 wt%, 40 wt%, 30 wt%, 20 wt% or 15 wt% of aerosol-former material.
  • the aerosol-generating composition or the aerosol-generating material comprises from about 1 to about 60 wt%, from about 5 to about 50 wt% or from about 10 to about 30 wt% aerosol-former material. In some embodiments, the aerosol-generating composition or the aerosol-generating material comprises from about 20 to about 40 wt% or from about 25 to about 35 wt% aerosol-former material, such as about 30 wt%.
  • the aerosol-generating composition or the aerosol-generating material may further comprise a binder.
  • the binder comprises one or more compounds selected from polysaccharide binders, such as alginate, pectin, cellulose or a derivative thereof, pullulan, carrageenan, agar and agarose; non-galactomannan gums, such as xanthan gum, and acacia gum; silica or silicone compounds, such as PDMS and sodium silicate; clays, such as kaolin; and polyvinyl alcohol.
  • the binder comprises one or more polysaccharide binders.
  • the binder is selected from alginate, pectin, and cellulose or a derivative thereof.
  • alginate is the only binder present in the aerosol-generating material.
  • the gelling agent comprises a combination of binders, such as alginate and at least one further binder (e.g. pectin, cellulose or a cellulose derivative).
  • binders such as alginate and at least one further binder (e.g. pectin, cellulose or a cellulose derivative).
  • cellulosic binders include, but are not limited to, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose (CMC), hydroxypropyl methylcellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate (CA), cellulose acetate butyrate (CAB), and cellulose acetate propionate (CAP).
  • CMC carboxymethylcellulose
  • HPMC hydroxypropyl methylcellulose
  • CA cellulose acetate
  • CAB cellulose acetate butyrate
  • CAP cellulose acetate propionate
  • the cellulose or derivative thereof is selected from hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethylcellulose (CMC), hydroxypropyl methylcellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate (CA), cellulose acetate butyrate (CAB), and cellulose acetate propionate (CAP).
  • CMC carboxymethylcellulose
  • HPMC hydroxypropyl methylcellulose
  • CAP cellulose acetate propionate
  • the cellulose derivative is CMC.
  • the aerosol-generating composition or the aerosol-generating material comprises from about 1 wt%, 5 wt%, 10, 15 or 20 wt% to about 80 wt%, 70 wt%, 50, 40, 30 or 20 wt% binder.
  • the aerosol-generating composition or the aerosol-generating material comprises from about 1 to about 80 wt%, from about 5 to about 70 wt%, or from about 10 to about 50 wt% binder.
  • the aerosol-generating composition or aerosol-generating material may comprise a filler.
  • a filler may help to reduce tackiness of the aerosol-generating material, for example if high levels of aerosol-former material are present.
  • the aerosol-generating composition or aerosol-generating material comprises filler in a total amount of about 1 to 80 wt% on a dry weight basis.
  • the aerosol-generating composition or aerosol-generating material comprises from about 30 to about 70 wt% filler, or from about 40 to about 60 wt% filler.
  • the aerosol-generating composition or aerosol-generating material comprises less than about 50 wt% of a filler, such as from about 1 wt% to 50 wt%, or 5 wt% to 40 wt%, or 5 wt% to 30 wt%, or 10 wt% to 20 wt%. In other embodiments, the aerosolgenerating composition or aerosol-generating material comprises less than 20 wt%, suitably less than 10 wt% or less than 5 wt% of a filler. In some cases, the aerosol-generating composition or aerosol-generating material comprises less than 1 wt% of a filler, and in some cases, comprises no filler.
  • the filler comprises (or is) one or more inorganic filler materials, such as calcium carbonate, perlite, vermiculite, diatomaceous earth, colloidal silica, magnesium oxide, magnesium sulphate, magnesium carbonate, and suitable inorganic sorbents, such as molecular sieves.
  • inorganic filler materials such as calcium carbonate, perlite, vermiculite, diatomaceous earth, colloidal silica, magnesium oxide, magnesium sulphate, magnesium carbonate, and suitable inorganic sorbents, such as molecular sieves.
  • the filler comprises (or is) one or more organic filler materials such as wood pulp; tobacco pulp; hemp fibre; cellulose and cellulose derivatives, such as microcrystalline cellulose and/or nanocrystalline cellulose.
  • microcrystalline cellulose may be formed by depolymerising cellulose by a chemical process (e.g. using an acid or enzyme).
  • a chemical process e.g. using an acid or enzyme.
  • One example method for forming microcrystalline cellulose involves acid hydrolysis of cellulose, using an acid such as HCI. The cellulose produced after this treatment is crystalline (i.e. no amorphous regions remain). Suitable methods and conditions for forming microcrystalline cellulose are well-known in the art.
  • the aerosol-generating composition or aerosol-generating material does not comprise any inorganic filler.
  • the aerosol-generating composition or aerosol-generating material comprises less than about 20 wt%, less than about 10 wt%, less than about 5 wt% or less than about 1 wt% calcium carbonate, such as chalk.
  • the aerosol-generating composition or aerosol-generating material comprises filler and the filler is fibrous.
  • the filler may be a fibrous organic filler material such as wood pulp, tobacco pulp, hemp fibre, cellulose or cellulose derivatives.
  • the fibrous organic filler material may be wood pulp, hemp fibre, cellulose or cellulose derivatives.
  • the fibrous filler is wood pulp. Without wishing to be bound by theory, it is believed that including fibrous filler may increase the tensile strength of the material. This may be particularly advantageous in examples wherein the aerosol-generating material is provided as a sheet, such as when an aerosol-generating material sheet circumscribes a rod of aerosolisable material.
  • the filler comprises microcrystalline cellulose and/or wood pulp.
  • compositions and materials described herein may comprise certain actives and/or flavourants, other than those compounds listed herein as key chemical markers.
  • Any actives and/or flavourants may be used to, for example, provide a consumer with a desirable experience and/or flavour in combination with the cigarette- 1 ike attributes conferred by the key chemical markers discussed herein.
  • key sense and/or taste chemical markers could be used (without the key flavour markers) to provide a composition having a cigarette-like sense and/or taste.
  • Such a composition could be combined or used with a known active or flavourants, such as menthol, for example to create a cigarette-like experience but with the flavour of menthol.
  • a drug such as CBD
  • CBD could be added to a composition of the invention to provide a cigarette-like experience whilst also experiencing the effects provided by the drug.
  • composition or the aerosol-generating material described herein additionally comprises an active substance.
  • the active substance as used herein may be a physiologically active material, which is a material intended to achieve or enhance a physiological response.
  • the active substance may for example be selected from nutraceuticals, nootropics, psychoactives.
  • the active substance may be naturally occurring or synthetically obtained.
  • the active substance may comprise for example nicotine, caffeine, taurine, theine, vitamins such as B6 or B12 or C, melatonin, cannabinoids, or constituents, derivatives, or combinations thereof.
  • the active substance may comprise one or more constituents, derivatives or extracts of tobacco, cannabis or another botanical.
  • the active substance comprises nicotine. In some embodiments, the active substance comprises caffeine, melatonin or vitamin B12.
  • the composition or the aerosol-generating material comprises from about 1wt%, 5wt%, 10wt%, 15wt%, 20wt% or 25wt% to about 70wt%, 60wt%, 50wt%, 45wt%, 40wt%, 35wt%, or 30wt% (calculated on a dry weight basis) of an active substance (such as tobacco and/or nicotine).
  • an active substance such as tobacco and/or nicotine
  • the composition or the aerosol-generating material may comprise a botanical extract.
  • the composition or the aerosol-generating material may comprise about 1 wt%, 3 wt%, 5 wt%, 10 wt%, 15 wt%, 20 wt %, 30 wt%, 35 wt% or 40 wt% to about to 30 wt%, 35 wt%, 40 wt%, 50 wt%, 60 wt%, 65 wt % or 70 wt% of botanical extract (all calculated on a dry weight basis), such as from about 1 to about 70 wt%, from about 5 to about 60 wt%, or from about 10 to about 50 wt%.
  • botanical extract includes an extract of any material derived from plants including, but not limited to, extracts, leaves, bark, fibres, stems, roots, seeds, flowers, fruits, pollen, husk, shells or the like.
  • the botanical extract may comprise an active compound naturally existing in a botanical, obtained synthetically.
  • Example botanicals are tobacco, eucalyptus, star anise, hemp, cocoa, cannabis, fennel, lemongrass, peppermint, spearmint, rooibos, chamomile, flax, ginger, ginkgo biloba, hazel, hibiscus, laurel, licorice (liquorice), matcha, mate, orange skin, papaya, rose, sage, tea such as green tea or black tea, thyme, clove, cinnamon, coffee, aniseed (anise), basil, bay leaves, cardamom, coriander, cumin, nutmeg, oregano, paprika, rosemary, saffron, lavender, lemon peel, mint, juniper, elderflower, vanilla, Wintergreen, beefsteak plant, curcuma, turmeric, sandalwood, cilantro, bergamot, orange blossom, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon
  • the mint may be chosen from the following mint varieties: Mentha Arventis, Mentha c.v., Mentha niliaca, Mentha piperita, Mentha piperita citrata c.v., Mentha piperita c.v, Mentha spicata crispa, Mentha cardifolia, Memtha longifolia, Mentha suaveolens variegata, Mentha pulegium, Mentha spicata c.v. and Mentha suaveolens.
  • the active substance comprises or is derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is tobacco.
  • the active substance comprises or derived from one or more botanicals or constituents, derivatives or extracts thereof and the botanical is selected from eucalyptus, star anise, cocoa and hemp.
  • Cannabinoids are a class of natural or synthetic chemical compounds which act on cannabinoid receptors (i.e. , CB1 and CB2) in cells that repress neurotransmitter release in the brain.
  • Cannabinoids may be naturally occurring (phytocannabinoids) from plants such as cannabis, from animals (endocannabinoids), or artificially manufactured (synthetic cannabinoids).
  • Cannabis species express at least 85 different phytocannabinoids, and are divided into subclasses, including cannabigerols, cannabichromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, and other cannabinoids.
  • Cannabinoids found in cannabis include, without limitation: cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabmolic acid (THCA), and tetrahydrocannabivarinic acid (THCV A).
  • CBD cannabigerol
  • flavour and “flavourant” refer to materials which, where local regulations permit, may be used to create a desired taste, aroma or other somatosensorial sensation in a product for adult consumers. They may include naturally occurring flavour materials, botanicals, extracts of botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, eugenol, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, aniseed (anise), cinnamon, turmeric, Indian spices, Asian spices, herb, Wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch,
  • the flavour comprises menthol, spearmint and/or peppermint.
  • the flavour comprises flavour components of cucumber, blueberry, citrus fruits and/or redberry.
  • the flavour comprises eugenol.
  • the flavour comprises flavour components extracted from tobacco.
  • the flavour comprises flavour components extracted from cannabis.
  • the flavour may comprise a sensate, which is intended to achieve a somatosensorial sensation which are usually chemically induced and perceived by the stimulation of the fifth cranial nerve (trigeminal nerve), in addition to or in place of aroma or taste nerves, and these may include agents providing heating, cooling, tingling, numbing effect.
  • a suitable heat effect agent may be, but is not limited to, vanillyl ethyl ether and a suitable cooling agent may be, but not limited to eucolyptol, WS-3.
  • the aerosol-generating composition or material may further comprise one or more other functional materials.
  • the one or more other functional materials may comprise one or more of pH regulators, colouring agents, preservatives, stabilizers, and/or antioxidants.
  • the aerosol-generating composition or material may comprise an acid.
  • the acid may be an organic acid.
  • the acid may be at least one of a monoprotic acid, a diprotic acid and a triprotic acid.
  • the acid may contain at least one carboxyl functional group.
  • the acid may be at least one of an alpha-hydroxy acid, carboxylic acid, dicarboxylic acid, tricarboxylic acid and keto acid.
  • the acid may be an alpha-keto acid.
  • the acid is lactic acid.
  • the acid is benzoic acid.
  • the acid may be an inorganic acid.
  • the acid may be a mineral acid.
  • the acid may be at least one of sulphuric acid, hydrochloric acid, boric acid and phosphoric acid.
  • the acid is levulinic acid.
  • an acid is particularly preferred in embodiments in which the aerosolgenerating composition or material comprises nicotine.
  • the presence of an acid may stabilise dissolved species in the slurry from which the aerosol-generating composition is formed.
  • the presence of the acid may reduce or substantially prevent evaporation of nicotine during drying of the slurry, thereby reducing loss of nicotine during manufacturing.
  • the aerosol-generating material may comprise a colourant.
  • the addition of a colourant may alter the visual appearance of the aerosol-generating material.
  • the presence of colourant in the aerosol-generating material may enhance the visual appearance of the aerosol-generating material and the aerosol-generating composition.
  • the aerosol-generating material may be colour-matched to other components of the aerosol-generating composition or to other components of a consumable comprising the aerosol-generating material.
  • colourants may be used depending on the desired colour of the aerosol-generating material.
  • the colour of aerosol-generating material may be, for example, white, green, red, purple, blue, brown or black. Other colours are also envisaged.
  • Natural or synthetic colourants such as natural or synthetic dyes, food-grade colourants and pharmaceutical-grade colourants may be used.
  • the colourant is caramel, which may confer the aerosolgenerating material with a brown appearance.
  • the colourant may be incorporated during the formation of the aerosol-generating material (e.g. when forming a slurry comprising the materials that form the aerosol-generating material) or it may be applied to the aerosol-generating material after its formation (e.g. by spraying it onto the aerosol-generating material).
  • the aerosol-generating material is formed as a sheet.
  • the aerosol-generating material sheet may be incorporated into the non-combustible aerosol provision system or consumable in sheet form.
  • the aerosol-generating material sheet may be incorporated as a planar sheet, as a gathered or bunched sheet, as a crimped sheet, or as a rolled sheet (i.e. in the form of a tube).
  • the aerosol-generating material of these embodiments may be included in the system/consumable as a sheet, such as a sheet circumscribing a rod of aerosolisable material (e.g. tobacco).
  • the aerosolgenerating material sheet may be formed on a wrapping paper which circumscribes an aerosolisable material such as tobacco.
  • the sheet may be shredded and then incorporated into the assembly, suitably mixed into an aerosolisable material such as cut rag tobacco.
  • the aerosol-generating material may be in the form of a sheet or layer having a thickness of about 0.015 mm to about 1.0 mm.
  • the thickness may be in the range of about 0.05 mm, 0.1 mm or 0.15 mm to about 0.5 mm or 0.3 mm, for example 0.1-3 mm or 0.15-3 mm.
  • a material having a thickness of 0.2 mm may be particularly suitable.
  • the aerosolgenerating material may comprise more than one layer, and the thickness described herein refers to the aggregate thickness of those layers.
  • the aerosol-generating material is too thick, then heating efficiency may be compromised. This adversely affects the power consumption in use. Conversely, if the aerosol-generating material is too thin, it may be difficult to manufacture and handle; a very thin material is harder to cast and may be fragile, compromising aerosol formation in use.
  • the thickness stipulated herein is a mean thickness for the material.
  • the aerosol-generating material thickness may vary by no more than 25%, 20%, 15%, 10%, 5% or 1%.
  • the aerosol-generating material in sheet form may have sufficient tensile strength such that it can be wound onto, or unwound from, a bobbin without breakages. In some examples, the aerosol-generating material in sheet form has a tensile strength of greater than or equal to about 250 N/m.
  • the carrier may be magnetic. This functionality may be used to fasten the carrier to the non-combustible aerosol provision device in use, or may be used to generate particular aerosol-generating material shapes.
  • the aerosol-generating composition may comprise one or more magnets which can be used to fasten the material to an induction heater in use.
  • the carrier may be substantially or wholly impermeable to gas and/or aerosol. This prevents aerosol or gas passage through the carrier layer, thereby controlling the flow and ensuring it is delivered to the user. This can also be used to prevent condensation or other deposition of the gas/aerosol in use on, for example, the surface of a heater provided in an aerosol generating assembly. Thus, consumption efficiency and hygiene can be improved in some cases.
  • the aerosol-generating material may be laminated to a carrier, such as a paper sheet.
  • the carrier may be a paper-backed foil; the paper layer abuts the aerosol-generating material and the properties discussed in the previous paragraphs are afforded by this abutment.
  • the foil backing is substantially impermeable, providing control of the aerosol flow path.
  • a metal foil backing may also serve to conduct heat to the aerosolgenerating material.
  • the foil layer of the paper-backed foil abuts the aerosol-generating material.
  • the foil is substantially impermeable, thereby preventing water provided in the aerosolgenerating material from being absorbed into the paper which could weaken its structural integrity.
  • a consumable is an article comprising or consisting of an aerosol-generating composition or material, part or all of which is intended to be consumed during use by a user.
  • a consumable may comprise one or more other components, such as an aerosol-generating composition or material storage area, an aerosol-generating composition transfer component, an aerosol generation area, a housing, a wrapper, a mouthpiece, a filter and/or an aerosol-modifying agent.
  • a consumable may also comprise an aerosol generator, such as a heater, that emits heat to cause the aerosol-generating composition to generate aerosol in use.
  • the heater may, for example, comprise combustible material, a material heatable by electrical conduction, or a susceptor.
  • a susceptor is a material that is heatable by penetration with a varying magnetic field, such as an alternating magnetic field.
  • the susceptor may be an electrically-conductive material, so that penetration thereof with a varying magnetic field causes induction heating of the heating material.
  • the heating material may be magnetic material, so that penetration thereof with a varying magnetic field causes magnetic hysteresis heating of the heating material.
  • the susceptor may be both electrically-conductive and magnetic, so that the susceptor is heatable by both heating mechanisms.
  • the device that is configured to generate the varying magnetic field is referred to as a magnetic field generator, herein.
  • An aerosol-modifying agent is a substance, typically located downstream of the aerosol generation area, that is configured to modify the aerosol generated, for example by changing the taste, flavour, acidity or another characteristic of the aerosol.
  • the aerosol-modifying agent may be provided in an aerosol-modifying agent release component, that is operable to selectively release the aerosol-modifying agent.
  • a non-combustible aerosol provision system comprising the consumable described herein and a non-combustible aerosol provision device.
  • Such devices are usually provided with one or more air inlet holes located away from a mouthpiece end of the system.
  • air inlet holes located away from a mouthpiece end of the system.
  • a user sucks on a mouthpiece connected to the mouthpiece end of the system, air is drawn in through the inlet holes and past the aerosol source.
  • There is a flow path connecting between the aerosol source and an opening in the mouthpiece so that air drawn past the aerosol source continues along the flow path to the mouthpiece opening, carrying some of the aerosol from the aerosol source with it.
  • the aerosolcarrying air exits the aerosol provision system through the mouthpiece opening for inhalation by the user.
  • Electronic cigarettes include a mechanism for activating the heater to vaporize the source liquid during use.
  • a manual activation mechanism such as a button, which the user presses to activate the heater.
  • the heater may be activated (i.e. supplied with electrical power) while the user is pressing the button, and deactivated when the user releases the button.
  • an automatic activation mechanism such as a pressure sensor arranged to detect when a user is drawing air through the device by inhaling on the mouthpiece.
  • the heater may be activated when it is detected the user is inhaling through the device and deactivated when it is detected the user has stopped inhaling through the device.
  • the cartomizer 30 further includes a mouthpiece 35 having an opening through which a user may inhale the aerosol from the aerosol generator.
  • the source liquid may be of a conventional kind used in e-cigarettes, for example comprising 0 to 5% nicotine dissolved in a solvent comprising glycerol, water, and/or propylene glycol.
  • the source liquid may also comprise flavourings.
  • the source liquid may further comprise the composition described herein. In some embodiments, the source liquid is the composition described herein.
  • the heating element In active use, i.e. when the heating element receives power from the battery, as controlled by the control circuitry, the heating element vaporizes source liquid in the vicinity of the heating element to generate an aerosol.
  • the aerosol is inhaled by a user through the opening in the mouthpiece 35. During user inhalation the aerosol is carried from the aerosol source to the mouthpiece opening along an air channel that connects between them.
  • the body 20 and cartomizer 30 are detachable from one another by separating in a direction parallel to the longitudinal axis LA, as shown in FIG. 1, but are joined together when the device 10 is in use by a connection, indicated schematically in FIG. 1 as 25A and 25B, to provide mechanical and electrical connectivity between the body 20 and the cartomizer 30.
  • the electrical connector on the body 20 that is used to connect to the cartomizer 30 also serves as a socket for connecting a charging device (not shown) when the body 20 is detached from the cartomizer 30.
  • the other end of the charging device can be plugged into an external power supply, for example a USB socket, to charge or to re-charge the cell/battery in the body 20 of the e-cigarette 10.
  • a cable may be provided for direct connection between the electrical connector on the body 20 and the external power supply and/or the device may be provided with a separate charging port, for example a port conforming to one of the USB formats.
  • the e-cigarette 10 is provided with one or more holes (not shown in FIG. 1) for air inlet. These holes connect to an air running passage (airflow path) through the e-cigarette 10 to the mouthpiece 35.
  • the air passage includes a region around the aerosol source and a section comprising an air channel connecting from the aerosol source to the opening in the mouthpiece 35.
  • airflow sensor e.g. a pressure sensor
  • the airflow sensor may operate in accordance with conventional techniques in terms of how it is arranged within the electronic cigarette 10 to generate airflow detection signals indicating when there is a flow of air through the electronic cigarette 10 (e.g. when a user inhales or blows on the mouthpiece 35).
  • the non-combustible aerosol provision system is a hybrid system to generate aerosol using a combination of aerosol-generating materials, one or a plurality of which may be heated.
  • Each of the aerosol-generating materials may be, for example, in the form of a solid, liquid or gel and may or may not contain nicotine.
  • the hybrid system comprises a liquid or gel aerosol-generating material and a solid aerosolgenerating material.
  • the liquid or gel aerosol-generating material may comprise a material or composition as described herein.
  • the solid aerosol-generating material may comprise, for example, tobacco or a non-tobacco product.
  • the distillation step (ii) and extraction step (iii) are carried out simultaneously in one single step.
  • the SDE method described herein is carried out in just one single step.
  • an additional distillation and/or extraction step is excluded.
  • the entire SDE method i.e. distillation step (ii) and extraction step (iii) is carried out simultaneously in one single piece of apparatus with no additional processing prior to removal of the extracted product from the apparatus.
  • the solvent is a non-polar solvent. In some embodiments, the solvent is a polar solvent.
  • polar solvent refers to any solvent having a dielectric constant of greater than or equal to 15.
  • non-polar solvent refers to any solvent having a dielectric constant of less than 15.
  • the solvent is immiscible with water.
  • the solvent is selected from the group consisting of n-butanol, cyclohexane, dichloromethane, ethyl acetate, heptane, hexane, methyl-t- butyl ether, 2- butanone, pentane, diisopropyl ether, diethyl ether, and mixtures thereof.
  • the solvent is selected from the group consisting of pentane, diethyl ether and mixtures thereof.
  • the solvent is a mixture of pentane and diethyl ether. The use of a mixture of pentane and ether is nontoxic, and may be easily replaced by ethanol after extraction of the volatile compounds of interest has been achieved.
  • the solvent is a mixture of pentane and diethyl ether, wherein the solvent comprises the pentane and diethyl ether in a weight ratio of pentane to diethyl ether of from about 10:1 to about 1 :10, such as from about 5:1 to about 1 :5, such as from about 3: 1 to about 1 :3, such as from 3:1 to 1 :1 , such as from about 3:1 to about 2:1 , such as about 2:1.
  • the solvent is a mixture of pentane and diethyl ether, wherein the solvent comprises the pentane and diethyl ether in a weight ratio of pentane to diethyl ether of about 2:1.
  • the period during which both the distillation step (ii) and the extraction step (iii) are carried out may be from about 1 to about 20 hours, such as from about 1 to about 7 hours, from about 2 to about 7 hours, from about 4 to about 7 hours, from about 4.5 to about 6.5 hours, from about 5 to about 6 hours, or about 6 hours.
  • the SFE process is performed for from about 0.5 to about 5 hours, such as from about 1 to about 4 hours, from about 2 to about 3 hours, or about 2.5 hours.
  • supercritical extraction is performed using a flow rate of extraction solvent (e.g. carbon dioxide) of from about 0.5, 0.8, or 1 kg/hrto about 2, 3 or 5 kg/hr. In some embodiments, supercritical extraction is performed using a flow rate of extraction solvent (e.g. carbon dioxide) of from about 0.1 to about 5 kg/hr, such as from about 0.8 to about 3 kg/hr, from about 1 to about 3 kg/hr, or about 1 kg/hr.
  • a flow rate of extraction solvent e.g. carbon dioxide
  • a lower pressure is used for a first period of time, followed by a higher pressure for a second period of time.
  • the lower pressure may be, for example, from about 50 to about 200 bar, such as from about 80 to about 120 bar, or about 100 bar.
  • the higher pressure may be, for example, from about 200 to about 500 bar, such as from about 250 to about 400 bar, such as from about 250 to about 350 bar, or about 300 bar.
  • the first period of time may be from about 0.5 to about 2 hours, such as about 1 hour.
  • the first period of time may be from about 0.5 to about 2 hours, such as from about 1 to about 2 hours, or about 1.5 hours.
  • the two fractions or extracts are combined (or simply collected in the same container). In some embodiments, the two fractions or extracts are collected separately and are not combined. In some embodiments, only the extract from the second period of time (at a higher pressure) is retained and/or used in the present invention.
  • the method may comprise:
  • the method may comprise:
  • one or more of the key chemical (e.g. taste) markers or additional key chemical (e.g. taste) markers are applied to the slurry during and/or after steps (b) and/or (c).
  • chemical markers which may first be isolated or purified may be applied to the slurry before or after drying.
  • the disclosures herein relating to constituents of the aerosol-generating composition and material apply equally to the slurry.
  • the slurry may comprise these constituents in any of the proportions given herein in relation to the composition of the aerosol-generating composition and material.
  • the slurry may further comprise a setting agent and/or a setting agent may be applied to the slurry.
  • the method may further comprise a step of setting the slurry.
  • forming the layer of the slurry and/or setting the slurry and/or drying the slurry at least partially, occur simultaneously (for example, during electrospraying).
  • the steps of forming the layer of the slurry, setting the slurry with any setting agent and drying the slurry occur sequentially, in that order.
  • Step (b) of forming a layer of the slurry typically comprises spraying, casting or extruding the slurry.
  • the slurry layer is formed by casting the slurry.
  • a setting agent such as a calcium source
  • a setting agent may be added to the slurry before or during step (b). This is appropriate in instances where gelation occurs relatively slowly, and thus the slurry may be, e.g. cast, after the setting agent is added.
  • a setting agent may be applied to the slurry layer after step (b).
  • the setting agent may be sprayed onto the slurry, for example, or may be preloaded onto the surface on which the slurry is layered.
  • a setting agent comprising a calcium source (such as calcium chloride or calcium citrate), may be added to a slurry containing alginate and/or pectin to form a calcium-crosslinked alginate/pectin gel.
  • a calcium source such as calcium chloride or calcium citrate
  • the total amount of the setting agent such as a calcium source, may be from about 0.5 to about 5 wt% (calculated on a dry weight basis).
  • the drying (c) may be done at ambient or raised temperatures.
  • the drying (c) removes from about 50 wt%, 60 wt%, 70 wt%, 80 wt% or 90 wt% to about 80 wt%, 90 wt% or 95 wt% (wet weight basis, WWB) of water in the slurry.
  • the drying (c) reduces the cast material thickness by at least 80%, suitably 85% or 87%. For instance, if the slurry is cast at a thickness of 2 mm, the resulting dried aerosolgenerating material may have a thickness of 0.2 mm.
  • the dried aerosol-generating material forms a sheet or layer with a thickness of about 0.015 mm to about 1 .0 mm.
  • the thickness may be in the range of about 0.05 mm, 0.1 mm or 0.15 mm to about 0.5 mm or 0.3 mm, for example 0.05-0.3 or 0.15-0.3 mm.
  • a material having a thickness of 0.2 mm may be particularly suitable.
  • Another aspect of the invention provides a method (referred to below as the second method) comprising providing the aerosol-generating material and combining the aerosol-generating material and tobacco material.
  • the slurry itself is an aspect of the invention.
  • the slurry solvent consists essentially of or consists of water.
  • the slurry comprises from about 50 wt%, 60 wt%, 70 wt%, 80 wt% or 90 wt% of solvent (WWB).
  • At least three of the following compounds nicotine; pseudooxynicotine and/or oxynicotine; lipid peroxidation inhibitor 1 ; scopoletin; N-(1-deoxy-1-fructosyl)proline; sucrose; Type I sucrose ester - GV - I0; Type I sucrose ester - GIV - I0; chlorogenic acid; 1,2, 3,4,5, 6-Hexahydro-7H-cyclopenta[b]pyridin-7- one; L-alpha-amino-1 H-pyrrole-1-hexanoic acid; retinol; quinic acid; Type I sucrose ester- Gill - I0; rutin; megastigmatrienone; 2-ethyl-5-methyl-pyridine; 16-hydroxy-hexadecanoicacid; Type III sucrose ester - GV - 10; and ferulic acid.
  • the aerosol may further comprise one or more of the sense and/or flavour markers, as described herein in relation to the composition.
  • the aerosol further comprises 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32 or 33) of the key smoke markers.
  • the aerosol further comprises 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten- 1-one; 5-methyl-2-furancarboxaldehyde; propanoic acid; 3-methyl-pyridine; 3-ethyl-pyridine; trimethyl-pyrazine; tiglic acid; 2-hydroxy-3-methyl-2-cyclopenten-1-one; 2-ethyl-phenol; 4- ethyl-phenol; 3-ethyl-phenol; 1-(1 H-pyrrol-2-yl)-ethanone; 2-methoxy-4-vinylphenol; 2-acetyl- 5-methylfuran; benzoic acid; triacetin; and maltol.
  • 1 or more e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17
  • the aerosol further comprises 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22) of the following compounds: 3-ethyl-2- hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; butanoic acid; 3-ethyl-pyridine; benzaldehyde; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; 2- methoxy-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4-vinylphenol; 4-ethyl-2- methoxy-phenol; octanoic acid; 2,6-dimethoxy-phenol; 2-methyl-propanoic acid; 3-methyl- butanoic acid; 1-(4-methylphenyl)-ethanone; vanillin; pentanoic acid; and benzeneacetic acid.
  • 1 or more e.g
  • the aerosol further comprises 1 or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3- methyl-pyridine; butanoic acid; 3-ethyl-pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; acetophenone; 2-ethyl-phenol; furaneol; 4-ethyl-phenol; 3-ethyl-phenol; 2-methoxy-4- vinylphenol; 4-ethyl-2-methoxy-phenol; and 2,6-dimethoxy-phenol.
  • 1 or more e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13
  • the aerosol further comprises 1 or more (e.g. 1, 2, 3, 4, 5, 6, 7 or 8) of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; 3-ethyl- pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; 2-ethyl-phenol; 4-ethyl-phenol; 3-ethyl- phenol; and 2-methoxy-4-vinylphenol.
  • 1 or more e.g. 1, 2, 3, 4, 5, 6, 7 or 8 of the following compounds: 3-ethyl-2-hydroxy-2-cyclopenten-1-one; 3-methyl-pyridine; 3-ethyl- pyridine; 2-hydroxy-3-methyl-2-cyclopenten-1-one; 2-ethyl-phenol; 4-ethyl-phenol; 3-ethyl- phenol; and 2-methoxy-4-vinylphenol.
  • compositions as described herein may be used in aerosol-free delivery systems that delivers the composition to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products (e.g. smokeless oral products) such as oral tobacco which includes snus or moist snuff, wherein the at least one substance may or may not comprise nicotine.
  • oral products e.g. smokeless oral products
  • oral tobacco which includes snus or moist snuff
  • the composition is a composition for use in an aerosol-free delivery system.
  • the composition may or may not comprise the key smoke markers described herein. This is because it may not be necessary for the smoke markers to be present for an FMC-like experience to be obtained when using the composition in an aerosol-free delivery system.
  • the invention provides a smokeless oral product comprising the composition described herein.
  • oral product and “smokeless oral product” may denote any smokeless product designed to be placed in the oral cavity of a user for a limited period of time, during which there is contact between the user's saliva and the product. These terms do not include non-combustible aerosol provision systems, such as tobacco heated products.
  • composition is a composition for oral delivery of the compounds present in the composition.
  • smokeless oral product generally describes a class of smokeless oral product which typically comprises solid particles having a mass median particle size measured by sieve analysis of between 0.01 and 5 mm, such as between 0.01 and 3 mm, such as between 0.01 and 1.0 mm.
  • the moisture content of the composition is at least about 20 wt% by weight of the total smokeless oral product, such as at least about 25 wt%, at least about 30 wt%, at least about 35 wt%, at least about 40 wt%, at least about 45 wt%, at least about 50 wt%, or at least about 60 wt% by weight of the smokeless oral product.
  • the composition can be provided to the user (e.g. in a smokeless oral product) in a portioned or a non-portioned format. Portioning the composition can reduce or eliminate the handling of the composition by the user, which can offer advantages in terms of better hygiene, convenience and/or ease of use.
  • the product may be suitable for buccal administration, i.e. the product is configured for insertion in the mouth of a user, i.e. a product having dimensions making it possible to insert and accommodate said product in the mouth, preferably between the gum and the upper lip.
  • Each of the pouches 101 encloses a composition according to the invention.
  • Each of said pouches 101 has dimensions making it suitable for insertion into the mouth of the user (buccal administration), e.g. a length or width in the order of 1-4 cm.
  • two or more interconnected pouches 101 have combined dimensions likewise making them suitable for insertion into the mouth (buccal administration), such that the user may accommodate multiple interconnected pouches 101 in their mouth.
  • a single pouch 101 may contain an amount of a composition less than what would be commonly used, e.g. less than what causes an effect/medical response in most individuals.
  • the user may choose to dispense more than one pouch, e.g.
  • the pouches 101 may more easily be stored/accommodated in the mouth, e.g. without risk of losing/swallowing. In fact, a single pouch 101 may be too small to most individuals, whereas two or more interconnected pouches would constitute a preferred size.
  • a first cross-section A and a second cross-section B of the pouches 101 are highlighted by dashed lines, illustrating the inner volume/chamber 104 intended for accommodating the composition.
  • Each of said pouches 101 are divided by a separation section 102, e g. formed by welding opposing sidewalls of the water-permeable material 103 together, whereby said separation section 103 may be considered a welding section.
  • the extracts were also analysed to determine whether the key chemical markers identified in Example 1 were present. The results are set out in the tables below.
  • the SFE extracts were found to generally have higher numbers of both the overall chemical markers and the key chemical markers. These extracts would therefore be expected to provide a more cigarette-like experience than the SDE extracts, when used to provide the flavour of a composition, for example in an aerosol-generating composition which could be used in a non-combustible aerosol provision system.
  • the C38 extract (Extract 1) has a slightly higher number of the key chemical markers.
  • the Paris extract (Extract 2) contains a higher number of key flavour markers.
  • Flavour could be considered to be the most important flavour dimension in a non-combustible aerosol provision system (e.g. in a vaping device), due to the volatility of the chemical markers or compounds associated with this flavour dimension.
  • Extract 2 might be expected to provide an overall improved cigarette-like experience than Extract 1.
  • Example 2 The extracts set out in Example 2 were then incorporated into a liquid composition and tested by five panellists, all of whom were current smokers.
  • Extract 2 was found to be the best.
  • Extract 4 was found to outperform Extract 1 slightly. This may be due to the higher number of key flavour markers found in Extract 4 compared to Extract 1 (11 vs. 6), despite the total number of key chemical markers being less for Extract 4 (23 vs 35).
  • Each of the extracts in Table 5 was chemically analysed to determine all of the compounds present therein. Separately, cigarettes comprising the Paris and C38 tobacco were burnt, and the compounds present in the smoke identified by collecting and analysing the smoke.
  • HTS-HRMS High throughput screening coupled with high resolution mass spec
  • GC-MS data Specifically, compounds could be identified based on exact monoisotopic mass and isotopic pattern from HTS-HRMS data and from GC-MS mass spectra, as compared to reference MS libraries and reference compounds.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Manufacture Of Tobacco Products (AREA)

Abstract

La présente invention concerne une composition qui produit une expérience de type cigarette fabriquée en usine (FMC) et un procédé de formation de la composition. La présente invention concerne également un consommable destiné à être utilisé dans un dispositif de fourniture d'aérosol non combustible, le consommable comprenant la composition, et un système de fourniture d'aérosol non combustible comprenant le consommable et un dispositif de fourniture d'aérosol non combustible.
PCT/EP2025/059344 2024-04-04 2025-04-04 Compositions pour produire une expérience de type cigarette fabriquée en usine Pending WO2025210259A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24168568.4A EP4627940A1 (fr) 2024-04-04 2024-04-04 Compositions et procédés
EP24168568.4 2024-04-04

Publications (1)

Publication Number Publication Date
WO2025210259A1 true WO2025210259A1 (fr) 2025-10-09

Family

ID=90718398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/059344 Pending WO2025210259A1 (fr) 2024-04-04 2025-04-04 Compositions pour produire une expérience de type cigarette fabriquée en usine

Country Status (2)

Country Link
EP (1) EP4627940A1 (fr)
WO (1) WO2025210259A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015062983A2 (fr) 2013-10-29 2015-05-07 British American Tobacco (Investments) Limited Appareil permettant de chauffer une matière pouvant être fumée
US20160113868A1 (en) * 2013-05-10 2016-04-28 Glaxosmithkline Llc Nicotine lozenge formulation
WO2016135331A1 (fr) 2015-02-27 2016-09-01 British American Tobacco (Investments) Limited Cartouche, éléments et procédés de génération de milieu inhalable
JP2017112935A (ja) * 2015-12-25 2017-06-29 株式会社東洋新薬 粉末青汁飲料
US20190302069A1 (en) * 2016-07-04 2019-10-03 British American Tobacco (Investments) Limited Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories
CN114901086A (zh) * 2019-11-08 2022-08-12 英美烟草(投资)有限公司 烟草处理

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160113868A1 (en) * 2013-05-10 2016-04-28 Glaxosmithkline Llc Nicotine lozenge formulation
WO2015062983A2 (fr) 2013-10-29 2015-05-07 British American Tobacco (Investments) Limited Appareil permettant de chauffer une matière pouvant être fumée
WO2016135331A1 (fr) 2015-02-27 2016-09-01 British American Tobacco (Investments) Limited Cartouche, éléments et procédés de génération de milieu inhalable
JP2017112935A (ja) * 2015-12-25 2017-06-29 株式会社東洋新薬 粉末青汁飲料
US20190302069A1 (en) * 2016-07-04 2019-10-03 British American Tobacco (Investments) Limited Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories
CN114901086A (zh) * 2019-11-08 2022-08-12 英美烟草(投资)有限公司 烟草处理

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZENGIN GOKHAN ET AL: "New insights into the chemical profiling, cytotoxicity and bioactivity of four Bunium species", FOOD RESEARCH INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 123, 1 September 2019 (2019-09-01), pages 414 - 424, XP085734010, ISSN: 0963-9969, [retrieved on 20190510], DOI: 10.1016/J.FOODRES.2019.05.013 *

Also Published As

Publication number Publication date
EP4627940A1 (fr) 2025-10-08

Similar Documents

Publication Publication Date Title
US20230037155A1 (en) Consumable comprising two different aerosol-generating materials for non-combustible aerosol provision device
JP7780530B2 (ja) 乾燥エアロゾル生成材料及びその使用
JP2024532246A (ja) エアロゾル発生材料
EP4627940A1 (fr) Compositions et procédés
EP4627941A1 (fr) Compositions et procédés
EP4627943A1 (fr) Compositions et procédés
EP4627942A1 (fr) Compositions et procédés
EP4627939A1 (fr) Procédés
KR20240053036A (ko) 키토산 및 부가적인 결합제를 포함하는 에어로졸 생성 재료
KR20240040080A (ko) 에어로졸 제공 디바이스와 함께 사용하기 위한 소모품
US20230118168A1 (en) Aerosol generation
CN116113338A (zh) 具有阻燃特性的气溶胶生成材料及其用途
CN116018075A (zh) 气溶胶生成
EP4599700A1 (fr) Articles générateurs d'aérosols et systèmes les comprenant
US20240373902A1 (en) Aerosol-generating material comprising guar gum and starch or modified starch
EP4573930A1 (fr) Consommable pour une formulation aérosoliasable
EP4599699A1 (fr) Compositions génératrices d'aérosols, articles et systèmes les comprenant
WO2024161118A2 (fr) Matériau de génération d'aérosol
JP2025510885A (ja) 透過性容器と植物材料由来の乾燥抽出物とを含む製品及びその使用
TW202432008A (zh) 氣溶膠產生材料
WO2024161116A2 (fr) Matériau de génération d'aérosol
CN118555913A (zh) 制造包括气溶胶生成材料的产品的方法
JP2025510838A (ja) エアロゾル生成材料及び収着材料を含む組成物並びにその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25717897

Country of ref document: EP

Kind code of ref document: A1